LMP genotypes | Patients (n=60) n (%) | Controls (n=61) n (%) | Positive for shared epitope | Negative for shared epitope | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Patients (n=35) n (%) | Controls (n=28) n (%) | Patients (n=25) n (%) | Controls (n=33) n (%) | ||||||||
TAP12-150A/A | 48 (80) | 41 (67.2) | 30 (85.7) | 18 (64.5) | 18 (72) | 23 (70) | |||||
TAP12-150A/C | 3 (5) | 1 (1.6) | 1 (2.9) | 1 (3.5) | 2 (8) | 0 | |||||
TAP12-150A/D | 1 (1.7) | 3 (5) | 0 | 1 (3.5) | 1 (4) | 2 (6) | |||||
TAP12-150B/C | 1 (1.7) | 0 | 1 (2.9) | 0 | 0 | 0 | |||||
TAP12-150D/D | 0 | 1 (1.6) | 0 | 0 | 0 | 1 (3) | |||||
TAP12-150F/F | 0 | 1 (1.6) | 0 | 1 (3.5) | 0 | 0 | |||||
TAP1 NA2-150 | 7 (11.6) | 14 (23) | 3 (8.5) | 7 (25) | 4 (16) | 7 (21) | |||||
TAP22-150A/A | 14 (23.4) | 14 (23) | 5 (14.3) | 5 (17.8) | 9 (36) | 9 (27.3) | |||||
TAP22-150A/B | 17 (28.4) | 15 (24.6) | 11 (31.4) | 8 (28.5) | 6 (24) | 7 (21.2) | |||||
TAP22-150A/C | 5 (8.3) | 5 (8.2) | 4 (11.4) | 2 (7.2) | 1 (4) | 3 (9) | |||||
TAP22-150A/D | 0 | 1 (1.6) | 0 | 1 (3.6) | 0 | 0 | |||||
TAP22-150A/E | 1 (1.6) | 2 (3.3) | 1 (2.9) | 1 (3.6) | 0 | 1 (3) | |||||
TAP22-150A/F | 4 (6.7) | 6 (9.8) | 3 (8.6) | 3 (10.7) | 1 (4) | 3 (9) | |||||
TAP22-150B/B | 7 (11.7) | 5 (8.2) | 3 (8.6) | 1 (3.6) | 4 (16) | 4 (12.2) | |||||
TAP22-150B/F | 1 (1.6) | 4 (6.6) | 1 (2.9) | 2 (7.2) | 0 | 2 (6.1) | |||||
TAP22-150C/C | 1 (1.6) | 2 (3.3) | 1 (2.9) | 0 | 0 | 2 (6.1) | |||||
TAP22-150C/D | 0 | 1 (1.6) | 0 | 1 (3.6) | 0 | 0 | |||||
TAP2 NA2-150 | 10 (16.7) | 6 (9.8) | 6 (17) | 4 (14.2) | 4 (16) | 2 (6.1) |
TAP12-150A, TAP12-150B, TAP12-150C, TAP12-150D are identical to TAP12-1500101,2-15002011, 2-1500301 and 2-1500401 respectively. TAP22-150A, TAP22-150B, TAP22-150E, TAP22-150F are identical to TAP2 2-1500101, 2-1500201, 2-1500102 and 2-1500103 respectively.
↵2-150 NA = not assigned.